TY - JOUR T1 - Window of Opportunity for Mitigation to Prevent Overflow of ICU capacity in Chicago by COVID-19 JF - medRxiv DO - 10.1101/2020.03.20.20040048 SP - 2020.03.20.20040048 AU - Sergei Maslov AU - Nigel Goldenfeld Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/24/2020.03.20.20040048.abstract N2 - We estimate the growth in demand for ICU beds in Chicago during the emerging COVID-19 epidemic, using state-of-the-art computer simulations calibrated for the SARS-CoV-2 virus. The questions we address are these:Will the ICU capacity in Chicago be exceeded, and if so by how much?Can strong mitigation strategies, such as lockdown or shelter in place order, prevent the overflow of capacity?When should such strategies be implemented?Our answers are as follows:The ICU capacity may be exceeded by a large amount, probably by a factor of ten.Strong mitigation can avert this emergency situation potentially, but even that will not work if implemented too late.If the strong mitigation precedes April 1st, then the growth of COVID-19 can be controlled and the ICU capacity could be adequate. The earlier the strong mitigation is implemented, the greater the probability that it will be successful. After around April 1 2020, any strong mitigation will not avert the emergency situation. In Italy, the lockdown occurred too late and the number of deaths is still doubling every 2.3 days. It is difficult to be sure about the precise dates for this window of opportunity, due to the inherent uncertainties in computer simulation. But there is high confidence in the main conclusion that it exists and will soon be closed.Our conclusion is that, being fully cognizant of the societal trade-offs, there is a rapidly closing window of opportunity to avert a worst-case scenario in Chicago, but only with strong mitigation/lockdown implemented in the next week at the latest. If this window is missed, the epidemic will get worse and then strong mitigation/lockdown will be required after all, but it will be too late.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external funding was receivedAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A ER -